A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjogren's Syndrome
Latest Information Update: 22 Sep 2020
At a glance
- Drugs Seletalisib (Primary)
- Indications Sjogren's syndrome
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors UCB
Most Recent Events
- 19 Sep 2020 Primary endpoint (Change from Baseline to Week 12 in the European League Against Rheumatism Sjgrens Syndrome Disease Activity Index (ESSDAI)) has not been met, as per results presented at the 20th Annual Congress of the European League Against Rheumatism
- 19 Sep 2020 Results published in the Rheumatology
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism